Lead Program

IBC-Ab002 Antibody

A novel anti-PD-L1 antibody tailored specifically to treat Neurodegenerative Diseases

IBC-Ab002 is uniquely designed to support its Mechanism of Action in Neurodegenerative diseases, including Alzheimer’s. It is a fully human therapeutic antibody with high affinity to block PD-L1 with Fc modifications that enable fast clearance from the circulation. In preclinical models of neurodegenerative diseases, short peripheral exposures of the antibody induced long-lasting beneficial changes in the CNS.

IBC-Ab002 properties:

  • Short half-life (fast clearance from the circulation)
  • High binding affinity to human PD-L1
    (sub-nanomolar range)
  • No Fc effector cytotoxic activity (ADCC/CDC)
  • Fully human; Fc-modified hIgG1

ImmunoBrain Approach with IBC-Ab002

IBC-Ab002 is uniquely positioned to tackle neurodegeneration with preclinical data suggesting simultaneous therapeutic effect on brain amyloid pathology, Tau pathologies, neuroinflammation, neuronal loss, and cognition.